Kevin Litwiler

1.4k total citations
29 papers, 1.1k citations indexed

About

Kevin Litwiler is a scholar working on Molecular Biology, Oncology and Bioengineering. According to data from OpenAlex, Kevin Litwiler has authored 29 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 9 papers in Oncology and 6 papers in Bioengineering. Recurrent topics in Kevin Litwiler's work include Analytical Chemistry and Sensors (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Protein Degradation and Inhibitors (5 papers). Kevin Litwiler is often cited by papers focused on Analytical Chemistry and Sensors (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Protein Degradation and Inhibitors (5 papers). Kevin Litwiler collaborates with scholars based in United States, United Kingdom and Singapore. Kevin Litwiler's co-authors include Frank V. Bright, Thomas A. Betts, Heidi Simmons, Clive Morris, Stephen Leong, David M. Wilson, Katie Kane, G Pöch, Gilad S. Gordon and Lia Gore and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Analytical Chemistry.

In The Last Decade

Kevin Litwiler

29 papers receiving 1.1k citations

Peers

Countries citing papers authored by Kevin Litwiler

Since Specialization

Citations

This map shows the geographic impact of Kevin Litwiler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Litwiler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Litwiler more than expected).

Fields of papers citing papers by Kevin Litwiler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Litwiler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Litwiler. The network helps show where Kevin Litwiler may publish in the future.

Co-authorship network of co-authors of Kevin Litwiler

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Litwiler. A scholar is included among the top collaborators of Kevin Litwiler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Litwiler. Kevin Litwiler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract LB174: OKI-219 is an inhibitor of PI3Kα H1047R that has brain penetrance and anti-tumor activity in a preclinical intracranial model of metastatic breast cancer 2024 ·Cancer Research ·(unknown), Molly A. Taylor, Kevin Litwiler, Qian Zhao, (unknown), Mark L. Boys, Yevgeniy Izrayelit, Richard Woessner, James D. Winkler	1
2	Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An In Vivo–In Vitro–In Silico Approach 2023 ·Molecular Pharmaceutics ·Joseph Piscitelli, Bart Hens, (unknown), Lance Wollenberg, Kevin Litwiler, Mark McAllister, Micaela B. Reddy	12
3	A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAFV600E-MutantKRASWild-Type Metastatic Colorectal Cancer 2023 ·The Oncologist ·Josep Tabernero, Eric Van Cutsem, Elena Garralda, David Tai, Filippo de Braud, Ravit Geva, Mark T. J. van Bussel, Katia Dotti, Elena Élez, Maria J. de Miguel, Kevin Litwiler, Danielle Murphy, Adrian Edwards, Van K. Morris	34
4	A phase I, single‐center, open‐label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [¹⁴C] encorafenib in healthy male subjects 2023 ·Pharmacology Research & Perspectives ·Lance Wollenberg, E. G. Hahn, Jason H. Williams, Kevin Litwiler	5
5	Abstract PR012: Novel strategy for RAS-pathway targeting: Initial results from a phase 1b/2 clinical trial of the oral HDAC inhibitor bocodepsin (OKI-179) combined with binimetinib in patients with RAS-pathway mutated solid tumors and NRAS-mutated melanoma 2023 ·Molecular Cancer Therapeutics ·Rodabe N. Amaria, (unknown), Katy K. Tsai, Robert Galamaga, Parisa Momtaz, Evan Pisick, (unknown), Harish P. Dave, Duncan Walker, Jennifer R. Diamond, Kevin Litwiler, Ryan J. Sullivan	1
6	First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors 2023 ·Cancers ·(unknown), (unknown), Bradley R. Corr, S. Lindsey Davis, Christopher H. Lieu, (unknown), Antonio Jimeno, D. Ross Camidge, (unknown), (unknown), (unknown), John A. DeMattei, (unknown), Todd Triplett, Sabine Eckhardt, Kevin Litwiler, James D. Winkler, Anthony D. Piscopio, Jennifer R. Diamond	7
7	A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma 2017 ·Cancer ·Jatin J. Shah, Jonathan L. Kaufman, Jeffrey A. Zonder, Adam D. Cohen, William Bensinger, Brandi Hilder, (unknown), Duncan Walker, Brian Tunquist, Kevin Litwiler, Mieke Ptaszynski, Robert Z. Orlowski, Sagar Lonial	48
8	Utilizing Physiologically Based Pharmacokinetic Modeling to Inform Formulation and Clinical Development for a Compound with pH-Dependent Solubility 2015 ·Journal of Pharmaceutical Sciences ·(unknown), Fernando Alvarez‐Núñez, Vincent Chow, Dominick Daurio, John A. Davis, Michael Dodds, Maurice G. Emery, Kevin Litwiler, Anne Paccaly, Joanna Peng, Brooke M. Rock, Larry C. Wienkers, (unknown), Zhigang Yu, Jan L. Wahlstrom	14
9	First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors 2015 ·Investigational New Drugs ·Patricia LoRusso, Priscila Gonçalves, (unknown), (unknown), Kevin Litwiler, (unknown), (unknown), (unknown), Heidi Simmons, Mieke Ptaszynski, Edward A. Sausville	40
10	An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614) 2015 ·Clinical Pharmacology Advances and Applications ·Lance Wollenberg, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Kevin Litwiler, Stacie Bell	2
11	A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer. 2012 ·Journal of Clinical Oncology ·Richard S. Finn, Milind Javle, Benjamin Tan, Colin D. Weekes, Johanna C. Bendell, Amita Patnaik, Gazala Khan, Dan Laheru, Lisa Anderson, Janna Christy‐Bittel, Emma Barrett, (unknown), Kevin Litwiler, Tanios Bekaii‐Saab	44
12	Identification of Alpha 1-Acid Glycoprotein (AAG) As a Potential Patient Selection Biomarker for Improved Clinical Activity of the Novel KSP Inhibitor ARRY-520 in Relapsed and Refractory Multiple Myeloma (MM) 2012 ·Blood ·Brian Tunquist, Karin Brown, Gary P. Hingorani, Sagar Lonial, Jonathan L. Kaufman, Jeffrey A. Zonder, Adam D. Cohen, William Bensinger, Robert Z. Orlowski, Jatin J. Shah, Brandi Hilder, (unknown), Kevin M. Koch, Kevin Litwiler, Duncan Walker	10
13	A phase 1 dose‐escalation study of ARRY‐520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias 2011 ·Cancer ·H. Jean Khoury, Guillermo Garcia‐Manero, Gautam Borthakur, (unknown), Maria Cielo Foudray, Martha Arellano, Amelia Langston, (unknown), (unknown), Kevin Litwiler, (unknown), Heidi Simmons, Adam I. Marcus, Mieke Ptaszynski, Hagop M. Kantarjian	56
14	ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study 2011 ·Blood ·Jatin J. Shah, Jeffrey A. Zonder, Adam D. Cohen, Robert Z. Orlowski, Raymond Alexanian, Sheeba K. Thomas, Donna Weber, Jonathan L. Kaufman, R. Donald Harvey, Duncan Walker, Kevin Litwiler, (unknown), Brandi Hilder, (unknown), Sagar Lonial	9
15	Investigation of β-Cyclodextrin Immobilized at Silica Surfaces by Fluorescence Spectroscopy 1992 ·Applied Spectroscopy ·Kevin Litwiler, Frank V. Bright	5
16	Effects of inaccurate reference lifetimes on interpreting frequency-domain fluorescence data 1990 ·Analytical Chemistry ·Kevin Litwiler, (unknown), Frank V. Bright	14
17	Regenerable fiber-optic-based immunosensor 1990 ·Analytical Chemistry ·Frank V. Bright, Thomas A. Betts, Kevin Litwiler	98
18	Advances in Multifrequency Phase and Modulation Fluorescence Analysis 1990 ·Critical Reviews in Analytical Chemistry ·Frank V. Bright, Thomas A. Betts, Kevin Litwiler	58
19	Correction for Excitation Beam Heterogeneities in Multifrequency Phase and Modulation Fluorescence 1990 ·Applied Spectroscopy ·Kevin Litwiler, Frank V. Bright	4
20	Simple fiber-optic sensor based on immobilized β-cyclodextrin 1990 ·Analytica Chimica Acta ·Kevin Litwiler, Gino C. Catena, Frank V. Bright	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact